BioSpace News Archive

OpSens Inc., a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary disease, has announced it has received CE marking for the OptoWire III, the latest generation of its flagship product.

The Advent-Harrington Impact Fund contributes to $215 million close of Advent Life Sciences’ funds focused on areas of high unmet medical need

Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2020 results

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021, at 11:10 a.m. Eastern Time.

A new clinical study1 establishes curcumin’s potential for supporting digestive health, with subsequent positive effect on mood and quality of life.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced agreements with Cosmo Pharmaceuticals NV (SIX: COPN) (“Cosmo”) to manufacture two key products; RedHill’s largest selling product in the U.S., Movantik®, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone

Sartorius Stedim Biotech, a leading partner of the biopharma industry, confirmed its preliminary figures for 2020 upon the release of its Universal Registration Document 2020 including the Annual Financial Report.

The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today an amendment of the agreement with Vyera Pharmaceuticals AG (“Vyera”) for the development of SLS-002 (intranasal racemic ketamine)

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will present at the 10th annual SVB Leerlink Global Healthcare Conference